Leerink on Insmed (INSM) as Shares Surge 26pct: 'we continue to view INSM as a core Rare Disease/blockbuster platform'
Tweet Send to a Friend
Leerink Partners analyst Joseph P. Schwartz reiterated an Outperform rating and $100.00 price target on Insmed (NASDAQ: INSM).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
